Incannex Healthcare Inc.
IXHLHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeIncannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. At a $38.8M market cap, Incannex Healthcare Inc. ranks as a micro-cap company within healthcare. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder.
Market Cap
$38.8M
Beta
2.83
P/E (TTM)
—
P/E (Fwd)
-1.87
EPS (TTM)
$-16.56
EPS (Fwd)
$-1.73
ROE
-117.2%
ROA
-32.2%
Cash
$74.5M
Total Debt
$114,000
Free CF
-$8.3M
52W Change
-80.2%
Annual Financials
Cash vs Debt
Where IXHL stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, IXHL finished 20.63% below its 150-day moving average ($4.12) and 45.13% below its 200-day moving average ($5.96). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is IXHL overbought or oversold?
At the September 3, 2026 close, IXHL's RSI(14) was 54.1, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Incannex Healthcare Inc. holds $74.5M in cash against $114K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$8.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -117.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $1.4M (2021) to $12K (2024), a 99% decline worth watching.
Incannex Healthcare Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, IXHL has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing IXHL.